United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Pharma Industry News Is Arcus Biosciences (RCUS) the dark horse of cancer immunotherapy after 26.7-month survival data? Arcus stock jumped after its domvanalimab-zimberelimab combo showed 26.7-month survival in gastric cancer. Find out what this means for its TIGIT pipeline. byVenkateshOctober 13, 2025